Tri Locum Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Tri Locum Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-68,750	Closed	-$5.48M	–	72
2022 Q2	$5.48M	Sell	68,750 -63,582	-48%	-$6.02M	2.25%	18
2022 Q1	$13.9M	Buy	+132,332	New	+$12.9M	5.44%	4
2021 Q4	–	Sell	-261,500	Closed	-$28.6M	–	58
2021 Q3	$28.6M	Buy	261,500 +3,736	+1%	+$388K	11.38%	1
2021 Q2	$24.1M	Sell	257,764 -35,662	-12%	-$3.28M	7.9%	3
2021 Q1	$27M	Buy	+293,426	New	+$24.8M	6.7%	6

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Tri Locum Partners's HZNP Position: Q3 2022 in Review

Tri Locum Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 68,750 shares — an estimated $5.48M sold.

Tri Locum Partners first reported a position in HZNP in Q1 2021 and held it in 5 quarters. The position peaked at $28.6M in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Tri Locum Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Tri Locum Partners sold 68,750 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $5.48M.
Tri Locum Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 5 quarters.
Tri Locum Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $28.6M in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Tri Locum Partners's 13F filing for Q3 2022, filed 14 Nov 2022.